Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH - Yahoo Finance

2 years ago 37

Webinar scheduled for Thursday, November 17, 2022, astatine 11:00 a.m. EST
Featuring cardinal sentiment person treatment connected existent attraction landscape

, /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical institution focused connected the improvement of oral cause transportation platforms, contiguous announced that it volition big a information presumption connected recently released information and efficacy information from the Phase 2 proceedings of its oral insulin campaigner (ORMD-0801) to trim liver abdominous contented successful Type 2 Diabetes ("T2D") patients with non-alcoholic steatohepatitis ("NASH") connected Thursday, November 17, 2022, astatine 11:00 a.m. Eastern Standard Time.

Oramed Logo

Professor Yaron Ilan, M.D., Director of the Department of Medicine astatine the Hebrew University-Hadassah Medical Center, and Joel Neutel, M.D., Director of Research, astatine the Orange County Research Center and Memorial Research Medical Clinic, volition supply commentary connected this information and the request for a NASH attraction that is harmless and well-tolerated.

The ceremonial presumption volition beryllium followed by a unrecorded question and reply league with Dr. Ilan and Dr. Neutel, who served arsenic superior investigators of this study.

To registry for the event, delight click the pursuing link: https://touchconference.zoom.us/webinar/register/WN_dy3jzksKQA6kBKZdT5a0_g

The unrecorded and archived webinar of this lawsuit whitethorn beryllium accessed connected Oramed's website nether Events and Presentations.

Professor Yaron Ilan, M.D.
Dr. Yaron Ilan is the Director of the Department of Medicine astatine the Hebrew University-Hadassah Medical Center. Dr. Ilan served arsenic the Vice Dean of the Hebrew University-Hadassah Medical School. Dr. Ilan was a Visiting Professor astatine Harvard University, moving connected caller immunotherapies. His main country of probe is improvement of immunomodulatory drugs for fatty liver disease, diabetes, inflammatory bowel illness and liver cancer. Dr. Ilan holds implicit 50 patents for discoveries based connected his innovative probe and has authored much than 300 articles. He is the inventor of respective drugs and aesculapian devices developed by pharmaceutical companies, respective that person reached the objective market. Dr. Ilan is the laminitis of respective companies and is simply a aesculapian manager and advisor for biotech companies.

Joel Neutel, M.D.
Dr. Neutel serves arsenic Director of Research astatine the Orange County Research Center successful Orange County, California and astatine the Memorial Research Medical Clinic successful Long Beach, California, wherever helium has served arsenic Study Principal Investigator connected respective 100 multinational cardiovascular & metabolic trials. Dr. Neutel has had extended acquisition serving the biopharmaceutical manufacture successful the areas of objective and world research, arsenic good arsenic selling strategical planning. After receiving his aesculapian grade astatine the University of Witwatersrand successful Johannesburg, South Africa, Dr. Neutel completed his internship and residency successful interior medicine astatine the Veterans Administration Medical Center successful Long Beach and The University of California, Irvine. Dr. Neutel has authored galore abstracts, diary articles and publication chapters. He has conducted extended probe successful specified disciplines arsenic cardiovascular medicine, endocrinology, and cardinal tense strategy disorders, with peculiar attraction to the pharmacotherapy of the diseases successful these areas.

About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is simply a level exertion pioneer successful the tract of oral transportation solutions for drugs presently delivered via injection. Established successful 2006, with offices successful the United States and Israel, Oramed has developed a caller Protein Oral Delivery (POD™) technology. Oramed is seeking to alteration the attraction of diabetes done its proprietary pb candidate, ORMD-0801, which is being evaluated successful 2 pivotal Phase 3 trials and has the imaginable to beryllium the archetypal commercialized oral insulin capsule for the attraction of diabetes. In addition, Oramed is processing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

For much information, delight sojourn www.oramed.com

Forward-Looking Statements
This property merchandise contains forward-looking statements. For example, we are utilizing forward-looking statements erstwhile we sermon the imaginable of ORMD-0801 to beryllium the archetypal commercialized oral insulin capsule for the attraction of diabetes. In addition, historical results of technological probe and objective trials bash not warrant that the conclusions of aboriginal probe oregon trials volition suggest identical oregon adjacent akin conclusions. These forward-looking statements are based connected the existent expectations of the absorption of Oramed only, and are taxable to a fig of factors and uncertainties that could origin existent results to disagree materially from those described successful the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of objective trials and merchandise improvement programs; difficulties oregon delays successful obtaining regulatory support oregon patent extortion for our merchandise candidates; contention from different pharmaceutical oregon biotechnology companies; and our quality to get further backing required to behaviour our research, improvement and commercialization activities. In addition, the pursuing factors, among others, could origin existent results to disagree materially from those described successful the forward-looking statements: changes successful exertion and marketplace requirements; delays oregon obstacles successful launching our objective trials; changes successful legislation; inability to timely make and present caller technologies, products and applications; deficiency of validation of our exertion arsenic we advancement further and deficiency of acceptance of our methods by the technological community; inability to clasp oregon pull cardinal employees whose cognition is indispensable to the improvement of our products; unforeseen technological difficulties that whitethorn make with our process; greater outgo of last merchandise than anticipated; nonaccomplishment of marketplace stock and unit connected pricing resulting from competition; laboratory results that bash not construe to arsenic bully results successful existent settings; our patents whitethorn not beryllium sufficient; and yet that products whitethorn harm recipients, each of which could origin the existent results oregon show of Oramed to disagree materially from those contemplated successful specified forward-looking statements. Except arsenic different required by law, Oramed undertakes nary work to publically merchandise immoderate revisions to these forward-looking statements to bespeak events oregon circumstances aft the day hereof oregon to bespeak the occurrence of unanticipated events. For a much elaborate statement of the risks and uncertainties affecting Oramed, notation is made to Oramed' s reports filed from clip to clip with the Securities and Exchange Commission.

Company Contact
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com